Clinical Trial Update: AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating AMG 176 in combination with azacitidine in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia was terminated, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• AMG 176
• AZACITIDINE (AZACITIDINE)

Snippet

Sponsor: Amgen | Conditions: Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 1 | Status: TERMINATED | Results posted: 2025-07-14